Navigation Links
Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
Date:9/20/2013

SALT LAKE CITY, Sept. 20, 2013 /PRNewswire-iReach/ -- On September 4th Dr. Phillip C. Hoopes, Jr., a surgeon at Hoopes Vision, successfully placed a light adjustable intraocular lens implant in a cataract patient as part of a new FDA clinical study. The surgery, which took place at Hoopes Vision's on-site surgery center, EyeSurg of Utah, was the first of its kind to take place in Utah. Dr. Hoopes said, "It was an honor to be the first in our state to implant this revolutionary new lens. At Hoopes Vision, we always strive to bring the newest and most promising technology to patients here in Utah, and this lens may change the way cataracts are treated."

The Light Adjustable Lens (LAL®) is designed to be the world's first and only intraocular lens that allows surgeons to change the power of the lens after it has been implanted in the patient's eye during a cataract surgery procedure.

Cataract development is a normal part of aging and typically results in a clouding of the natural lens of the eye, thereby negatively affecting vision. This problem is solved by removing the cataract via a surgical procedure in which the cataract is replaced by a clear synthetic lens, referred to as an intraocular lens. Currently, no commercially available lens in the world has the ability to be adjusted after implantation in the eye, and therefore, many patients still need glasses after surgery for optimal vision. The LAL is designed to give patients excellent distance vision without the need for glasses.

The LAL is currently commercially available in Europe and Mexico. However, before the LAL can be made available to patients in the U.S. it must be approved for sale by the FDA. This requires completion of a series of clinical studies, the third and final phase of which has recently commenced. The study involves the treatment of 600 eyes at 15 investigative sites across the country.

Hoopes Vision is excited to be one of these exclusive sites currently enrolling patients for the phase III study and welcomes interest in participation from prospective patients. If you'd like more information and to determine if you might qualify for the study, please contact the Hoopes Vision Clinical Research Center at (801) 988-7342.

Caution: The LAL is an investigational device and is limited by United States federal law to investigational use only.

# # #

If you'd like more information, please call the Hoopes Vision Clinical Research Center at (801) 988-7342 or email research@hoopesvision.com.

Media Contact: Steve Linn, Hoopes Vision, (801) 988-7342, research@hoopesvision.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Hoopes Vision
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Deputy HHS Secretary, Investors and Entrepreneurs to Share Their Vision of Upcoming New Era in Health Care
2. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
3. Hubble Telemedical Welcomes Healthcare Visionary Jonathan Lord, M.D. to Its Board of Directors
4. RainTree Oncology Expands Management As Strategic Vision For Community Oncology Unfolds
5. Users of PediaVisions Spot Vision Screener Honor Childrens Eye Health and Safety Month with Back-to-School Screenings
6. CRO Solutions, Inc. Announces Opening of New Division - VxP Pharma Services, Inc.
7. Dr. Sheldon Pinnell, The Founding Father Of Topical Antioxidants, Leading Scientist Behind SkinCeuticals, And Chief Emeritus Of The Division Of Dermatology At Duke University, Dies At 76
8. CMS Proposes Permanent Medicare Payment for VisionCares Telescope Implant for Macular Degeneration
9. Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk
10. New Vision Hope For Millions Undergoing Cataract Surgery
11. Industry Veteran, John Maroney, to Join ForSight VISION5 as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):